Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Checkpoint inhibitor therapy and psoriasis: a case series.
Hussain K, Kanji A, Zaheri S, Malek D, Terlizzo M, Weir J, Turajlic S, Fearfield L. Hussain K, et al. Among authors: turajlic s. Clin Exp Dermatol. 2023 Mar 1;48(3):254-256. doi: 10.1093/ced/llac095. Clin Exp Dermatol. 2023. PMID: 36763756 No abstract available.
Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.
Au L, Fendler A, Shepherd STC, Rzeniewicz K, Cerrone M, Byrne F, Carlyle E, Edmonds K, Del Rosario L, Shon J, Haynes WA, Ward B, Shum B, Gordon W, Gerard CL, Xie W, Joharatnam-Hogan N, Young K, Pickering L, Furness AJS, Larkin J, Harvey R, Kassiotis G, Gandhi S; Crick COVID-19 Consortium; Swanton C, Fribbens C, Wilkinson KA, Wilkinson RJ, Lau DK, Banerjee S, Starling N, Chau I; CAPTURE Consortium; Turajlic S. Au L, et al. Among authors: turajlic s. Nat Med. 2021 Aug;27(8):1362-1366. doi: 10.1038/s41591-021-01387-6. Epub 2021 May 26. Nat Med. 2021. PMID: 34040262 Free PMC article.
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
Larkin J, Marais R, Porta N, Gonzalez de Castro D, Parsons L, Messiou C, Stamp G, Thompson L, Edmonds K, Sarker S, Banerji J, Lorigan P, Evans TRJ, Corrie P, Marshall E, Middleton MR, Nathan P, Nicholson S, Ottensmeier C, Plummer R, Bliss J, Valpione S, Turajlic S. Larkin J, et al. Among authors: turajlic s. Cell Rep Med. 2024 Mar 19;5(3):101435. doi: 10.1016/j.xcrm.2024.101435. Epub 2024 Feb 27. Cell Rep Med. 2024. PMID: 38417447 Free PMC article. Clinical Trial.
Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinoma.
Houlston R, Culliford R, Lawrence S, Mills C, Tippu Z, Chubb D, Cornish A, Browining L, Kinnersley B, Bentham R, Sud A, Pallikonda H, Frangou A, Gruber A, Litchfield K, Wedge D, Larkin J, Turajlic S. Houlston R, et al. Among authors: turajlic s. Res Sq [Preprint]. 2023 Dec 6:rs.3.rs-3675752. doi: 10.21203/rs.3.rs-3675752/v1. Res Sq. 2023. PMID: 38106039 Free PMC article. Preprint.
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review.
Prelaj A, Miskovic V, Zanitti M, Trovo F, Genova C, Viscardi G, Rebuzzi SE, Mazzeo L, Provenzano L, Kosta S, Favali M, Spagnoletti A, Castelo-Branco L, Dolezal J, Pearson AT, Lo Russo G, Proto C, Ganzinelli M, Giani C, Ambrosini E, Turajlic S, Au L, Koopman M, Delaloge S, Kather JN, de Braud F, Garassino MC, Pentheroudakis G, Spencer C, Pedrocchi ALG. Prelaj A, et al. Among authors: turajlic s. Ann Oncol. 2024 Jan;35(1):29-65. doi: 10.1016/j.annonc.2023.10.125. Epub 2023 Oct 23. Ann Oncol. 2024. PMID: 37879443 Review.
Interpretability of radiomics models is improved when using feature group selection strategies for predicting molecular and clinical targets in clear-cell renal cell carcinoma: insights from the TRACERx Renal study.
Orton MR, Hann E, Doran SJ, Shepherd STC, Ap Dafydd D, Spencer CE, López JI, Albarrán-Artahona V, Comito F, Warren H, Shur J, Messiou C, Larkin J, Turajlic S; TRACERx Renal Consortium; Koh DM. Orton MR, et al. Among authors: turajlic s. Cancer Imaging. 2023 Aug 14;23(1):76. doi: 10.1186/s40644-023-00594-3. Cancer Imaging. 2023. PMID: 37580840 Free PMC article. Clinical Trial.
Copy number architectures define treatment-mediated selection of lethal prostate cancer clones.
Hasan AMM, Cremaschi P, Wetterskog D, Jayaram A, Wong SQ, Williams S, Pasam A, Trigos A, Trujillo B, Grist E, Friedrich S, Vainauskas O, Parry M, Ismail M, Devlies W, Wingate A, Linch M, Naceur-Lombardelli C; PEACE consortium; Swanton C, Jamal-Hanjani M, Lise S, Sandhu S, Attard G. Hasan AMM, et al. Nat Commun. 2023 Aug 10;14(1):4823. doi: 10.1038/s41467-023-40315-9. Nat Commun. 2023. PMID: 37563129 Free PMC article.
Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond.
Gerard C, Shum B, Nathan P, Turajlic S. Gerard C, et al. Among authors: turajlic s. Immunooncol Technol. 2023 Jun 8;19:100386. doi: 10.1016/j.iotech.2023.100386. eCollection 2023 Sep. Immunooncol Technol. 2023. PMID: 37483658 Free PMC article. Review.
122 results